Our office has recently begun accepting cases where people have suffered eye or vision damage due to a condition called pigmentary maculopthy due to taking the prescription drug Elmiron to treat interstitial cystitis. Our early investigation has shown that the manufacturer was aware that this drug was producing eye problems while it was being developed and that there were adverse event reports submitted to the FDA concerning this issue shortly after the drug was released in the marketplace. Most alarmingly, there are no warnings on the label for this drug and no precautions or contraindications for its use in the United States even though Canadian authorities have been requiring a warning. Our office stands ready to assist users of Elmiron recover the compensation they deserve. Contact us for a free, no-obligation consultation if you have any concerns about whether the use of Elmiron has caused injury or damage to your eyes or vision.